Substituted aryl 1,4-pyrazine derivatives

Details Substituted aryl 1,4-pyrazine derivatives Substituted aryl 1,4-pyrazine derivatives

2006-01-31

2006-01-31

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S336000, C206S828000

Reexamination Certificate

active

06992087

ABSTRACT:
Substituted aryl 1,4-pyrazine derivatives of formula I as defined hereinand their use in treating anxiety disorders, depression and stress related disorders are disclosed.

REFERENCES:
patent: 5872136 (1999-02-01), Anthony et al.
patent: 5880140 (1999-03-01), Anthony
patent: 5883105 (1999-03-01), Anthony
patent: 6043260 (2000-03-01), Chen et al.
patent: WO 97/35901 (1997-10-01), None
patent: WO 97/36886 (1997-10-01), None
patent: WO 97/36898 (1997-10-01), None
patent: WO 98/29119 (1998-07-01), None
patent: WO 98/38174 (1998-09-01), None
patent: WO 01/60806 (2001-08-01), None
Keller et al, “Corticotropin Releasing Hormone: Therapeutic Implications and Medicinal Chemistry Developments” Bioorganic & Medicinal Chemistry Letters, vol. 8(6), pp. 1213-123 (2000).
Kobayashi et al, “Nucleosides, XIX. Synthesis, properties and chemical behavior of 1(3)-methyl-6,7-diphenyl-3(1)-(beta-D-ribofuranosyl) lumazine derivatives” Chemische Berichte, vol. 109(9), pp. 3194-3207 (1976).
Hawley's Condensed Chemical Dictionary, 12th ed., Richard J. Lewis, Sr. , © 1993 by Van Nostrand Reinhold, p. 594.
Concise Chemical Dictionary, edited by Drs. Hans-Dieter Jakubke and Hans Jeschkelt, © 1993 by Walter de Gruyter & Co., p. 490.
McGraw-Hill Dictionary of Chemical Terms, 3rd ed. edited by Sybil P. Parker, © 1984 McGraw-Hill, Inc., p. 200.
Kehne and De Lombert, “Non-Peptidic CRF1 Receptor Treatment of Anxiety, Depression and Stress Disorders” Current Drug Targets, vol. 1(5), pp. 467-493 (2002).
Dautzenberg and Hauger, “The CRF peptide family and their receptors: yet more partners discovered” Trends in Pharmacological Sciences, vol. 23(2), pp. 71-77 (Feb. 2002).
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Petrusewitz and Kaliszan, “Antiaggregatory activity of imidazoline drugs and chemicals as a function of their structure” Agents and Actions, vol. 24 (1/2), pp. 204-209 (1988).
Jens Ahman, et al, “An Improved Method for the Palladium-Catalyzed Animation of Aryl Triflates”, Tetrahedron Letters, vol. 38, No. 36, 1997, pp. 6363-6366.
Mihály Arat∘, et al, “Elevated CSF CRF in Suicide Victims”, Society of biological Psychiatry, 1989; 25:355-359.
Csaba M. Banki, M.D., et al, “CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depression and Schizophrenia”, Am J Psychiatry 144:7, 1987, pp. 873-877.
D.R. Britton, et al, “Intraventricular Corticotropin-Releasing Factor Enhances Behavioral Effects of Novelty”, Life Sciences, vol. 31, 1982, pp. 363-367.
Karen Thatcher Britton, et al, “Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test”, Psychopharmacology, 94, 1988, pp. 306-311.
Adrian J. Dunn, et al, “Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?”, Brain Research Reviews, 15, 1990, pp. 71-100.
Paul J. Fagan, et al, “Using Intelligent/Random Library Screening to Design Focused Libraries for the Optimization of Homogenous Catalysts: Ullmann Ether Formation”, American Chemical Society, 122, 2000, pp. 5043-5051.
Randal D. France, et al, “CSF Corticotropin-Releasing Factor-Like Immunoactivity in Chronic Pain Patients with and without Major Depression”, Society of Biological Psychiatry, 23, 1988, pp. 86-88.
Dimitri E. Grigoriadis, et al, “Effects of Chronic Antidepressant and Benzodiazepine Treatment on Corticotropin-Reseasing-Factor Receptors in Rat Brain and Pituitary”, Neuropsychopharmacology, 1989, vol. 2, No. 1, pp. 53-60.
Prudencio S. Herradura, et al, “Copper-Mediated Cross-Coupling of Aryl Boronic Acids and Alkyl Thiols”, Organic Letters, vol. 2, No. 14, 2000, pp. 2019-2022.
Adam F. Littke, et al, “Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions”, American Chemical Society, 122, 2000, pp. 4020-4028.
Joseph A. Miller, et al, “Synthesis of Functionally Substituted Unsymmetrical Biaryls via a Novel Double Metal Catalyzed Coupling Reaction”, Tetrahedron Letters, 39, 1998, pp. 7275-7278.
Terence N. Mitchell, “Palladium-Catalysed Reactions of Organotin Compounds”, Fachbereich Chemie, 1991, pp. 803-815.
Norio Miyaura, et al, “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds”, Chemical Reviews, 95, 1995, pp. 2457-2483.
J. E. Morley, et al, “Neuropeptides: Conductors of the Immune Orchestra”, Life Sciences, vol. 41, pp. 527-544.
Hideshi Nakamura, et al, “Synthesis and Chemiluminescence of 5-[(2-Pyridyl)-, (2-Pyrazinyl)-, and (Substituted 2-pyrazinyl)amino]-1,2,4-trioxanes”, The Chemical Society of Japan, 1988, pp. 3776-3778.
Charles B. Nemeroff, et al, “Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients”, Science vol. 226, 1984, pp. 1342-1344.
Charles B. Nemeroff, et al, “Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims”, Arch. Gen. Psychiatry, vol. 45, 1988, pp. 577-579.
Akihiro Ohta, et al, “Syntheses and Reactions of Some 2,5-Disubstituted Pyrazine Monoxides”, Chem. Pharm. Bull. 27, 9, 1979, pp. 2027-2041.
Jean Rivier, et al, “Characterization of rat hypothalamic corticotropin-releasing factor”, Proc. Natl. Acad. Sci. vol. 80, 1983, pp. 4851-4855.
Robert M. Sapolsky, “Hypercortisolism Among Socially Subordinate Wild Baboons Originates at the CNS Level”, Arch. Gen. Psychiatry, vol. 46, 1989, pp. 1047-1051.
Scott E. Schaus, “Practical Synthesis of Enantiopure Cyclic 1,2-Amino Alcohols via Catalytic Asymmetric Ring Opening of Meso Epoxides”, J. Org. Chem., 62, 1987, pp. 4197-4199.
Errol B. De Souza, et al, “Corticotropin-releasing Factor Receptors Are Widely Distributed within the Rat Central Nervous System: An Autoradiographic Study”, The Journal of Neuroscience, vol. 5, pp. 3189-3203.
N. R. Swerdlow, et al, “Corticotropin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide”, Psychopharmacology, 88, 1986, pp. 147-152.
Karen E. Torraca, et al, “An Efficient Intermolecular Palladium-Catalyzed Synthesis of Aryl Ethers”, J. Am. Chem. Soc., 123, 2001, pp. 10770-10771.
Wylie Vale, et al, “Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and ∘-Endorphin”, Science, vol. 213, 1981, pp. 1394-1397.
John P. Wolfe, et al, “An Ammonia Equivalent for the Palladium-Catalyzed Animation of Aryl Halides and Triflates”, Tetrahedron Letters, vol. 38, No. 36, 1997, pp. 6367-6370.
John P. Wolfe, et al, “Simple, Efficient Catalyst System for the Palladium-Catalyzed Animation of Aryl Chlorides, Bromides, and Triflates”, J. Org. Chem., 65, 2000, pp. 1158-1174.
XP002233213, Chemical Abstract, vol. 121, No. 28, (1994), p. 1111, column 2.
XP002233214, Chemical Abstract, vol. 127, No. 2, (1997), p. 559.
George Battaglia, et al, “Characterization of Corticotropin-Releasing Factor Receptor-Mediated Adenylate Cyclase Activity in the Rat Central Nervous System”, Synapse 1:572 (1987).
Craig W. Berridge, et al, “Corticotropin Releasing Factor Antagonist Reverses the Stress-Induced Changes of Exploratory Behavior in Mice”, Hormones and Behavior vol. 21, pp. 393-401 (1987).
Craig W. Be

Affiliated with

Also associated with

Rating

Substituted aryl 1,4-pyrazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted aryl 1,4-pyrazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aryl 1,4-pyrazine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3529507